期刊
EUROPEAN JOURNAL OF HAEMATOLOGY
卷 95, 期 6, 页码 545-550出版社
WILEY
DOI: 10.1111/ejh.12530
关键词
iron overload; hereditary hemochromatosis; transfusional siderosis; deferasirox; chelation therapy; phlebotomy; erythrocy-tapheresis
类别
This open-label, prospective, phase 2 study evaluated the safety and efficacy of deferasirox (10 +/- 5 mg/kg/d) in patients with hereditary hemochromatosis (HH) and iron overload refractory to or intolerant of phlebotomy. Ten patients were enrolled and all completed the 12-month treatment period. There were significant decreases from baseline to end of study (i.e., 12 months) in median serum ferritin (P < 0.001), mean transferrin saturation (P < 0.05), median liver iron concentration (P < 0.001), and mean alanine aminotransferase (P < 0.05). The median time to achieve serum ferritin reduction >= 50% compared to baseline was 7.53 months. The most common adverse events were mild, transient diarrhea (n = 5) and nausea (n = 2). No patient experienced an increase in serum creatinine that exceeded the upper limit of normal. These data confirm that deferasirox was well tolerated and effective in reducing iron burden in patients with hereditary hemochromatosis and could be a safe alternative to phlebotomy in selected patients.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据